Head-to-head evidence
Evinacumab vs HRS-7249
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: ANGPTL3 · full Atherosclerotic Cardiovascular Disease pipeline
Evinacumab · Evkeeza
Marketed by Regeneron Pharmaceuticals
NCT03399786 · Phase 3 · completed
The trial randomized 65 participants to evinacumab or placebo and masked participants, care providers, investigators, and outcome assessors. Its primary LDL-C endpoint was statistically significantly improved with evinacumab, but LDL-C is a surrogate laboratory endpoint rather than a hard clinical or endoscopic measure.
HRS-7249
Developed by Jiangsu Hengrui Pharmaceuticals
NCT06541457 · Phase 1 · completed
This is a randomized, blinded, placebo-controlled study, which is a sound design, but its primary measure is adverse-event safety rather than a lipid or cardiovascular efficacy outcome, and no results have been posted yet.
Next expected readout: June 2027 · NCT07308392 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Evinacumab's landscape · HRS-7249's landscape